Evidence map›Paper›PMID 29728993›Full record

ReviewInternational urology and nephrology2018

The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.

Mehmet Kanbay, Emine M Onal, Baris Afsar, Tuncay Dagel, Aslihan Yerlikaya, Adrian Covic, Nosratola D Vaziri

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04689074 (Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano), which is not on this map. Cited by 85 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 4 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04689074 completednot on this mapstarted 2021, after this paper: background citation

Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi

TypeobservationalSponsorAzienda Ospedaliero-Universitaria Consorziale Policlinico di BariRan2021 to 2022Enrolled150ConditionsAutosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), IgA Nephropathy (IgAN)ArmsBiological sample collection, Questionnaire, Medical examination
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Mehmet KanbayDivision of Nephrology, Department of Medicine, Koc University School of Medicine, Rumelifeneri Yolu, Sariyer, 34450, Istanbul, Turkey. mkanbay@ku.edu.tr.ORCID http://orcid.org/0000-0002-1297-0675
Emine M OnalKoc University School of Medicine, Istanbul, Turkey.
Baris AfsarDivision of Nephrology, Department of Medicine, Suleymen Demirel University School of Medicine, Isparta, Turkey.
Tuncay DagelDivision of Nephrology, Department of Medicine, Koc University School of Medicine, Rumelifeneri Yolu, Sariyer, 34450, Istanbul, Turkey.
Aslihan YerlikayaKoc University School of Medicine, Istanbul, Turkey.
Adrian CovicNephrology Department, Dialysis and Renal Transplant Center, "Dr. C.I. Parhon" University Hospital, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.
Nosratola D VaziriDivision of Nephrology and Hypertension, University of California, Irvine, CA, USA.
Koç University · TRGrigore T. Popa University of Medicine and Pharmacy · ROSüleyman Demirel University · TRUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) has been shown to result in profound changes in the composition and functions of the gut microbial flora which by disrupting intestinal epithelial barrier and generating toxic by-products contributes to systemic inflammation and the associated complications. On the other hand, emerging evidence points to the role of the gut microbiota in the development and progression of CKD by provoking inflammation, proteinuria, hypertension, and diabetes. These observations demonstrate the causal interconnection between the gut microbial dysbiosis and CKD. The gut microbiota closely interacts with the inflammatory, renal, cardiovascular, and endocrine systems via metabolic, humoral, and neural signaling pathways, events which can lead to chronic systemic inflammation, proteinuria, hypertension, diabetes, and kidney disease. Given the established role of the gut microbiota in the development and progression of CKD and its complications, favorable modification of the composition and function of the gut microbiome represents an appealing therapeutic target for prevention and treatment of CKD. This review provides an overview of the role of the gut microbial dysbiosis in the pathogenesis of the common causes of CKD including hypertension, diabetes, and proteinuria as well as progression of CKD.

Indexed as

Gastrointestinal MicrobiomeAnimalsDiabetes MellitusDysbiosisHumansHypertensionInflammationKidneyProbioticsProteinuriaRenal Insufficiency, ChronicChronic kidney diseaseDiabetesGut microbiotaHypertensionInflammationProteinuria

Identifiers

PMID29728993
OpenAlexW2802126353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.